Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-108 + penpulimab + chemotherapy in advanced solid tumors
NCT06825494Phase 2Recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Apr 2025
- Primary completion
- Mar 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of LM-108 in solid tumor (advanced stage), gastric cancer (GC) and gastroesophageal junction cancer (5 arms), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days and Progression-Free Survival at 10 months. Started Apr 2025; status: recruiting.
02
Drugs
LM-108
03
Conditions
solid tumor (advanced stage)gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT06825494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06825494.